Drugs / NRICM102
NRICM102
also known as
NRICM102 decoction
Traditional medicine (herbal / TCM) targets ACE2, TNF via inhibition
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT07583992 | Jun 2026 → Mar 2027 expected | pneumonia | National Research Institute of Chinese Medicine, Ministry of Health and Welfare | Not yet recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06690203 | Sep 2024 → Oct 2025 overdue | lower respiratory tract disorder | Taichung Veterans General Hospital | Enrolling by invitation | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NRICM102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07583992 ↗ |
| Known as | NRICM102 decoction | “This study is to assess safety and efficacy of NRICM102 decoction in participants with CLRD.” NCT06690203 ↗ |
| Action | Inhibit | “inhibit the interaction between the SARS-CoV-2 spike protein and the human angiotensin-converting enzyme 2 (ACE2) receptor” NCT07583992 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “A traditional Chinese medicine formula” NCT06690203 ↗ |
| Route | Oral | “Oral administration” NCT07583992 ↗ |
| Target | ACE2 | “The main ingredients are believed to inhibit the interaction between the SARS-CoV-2 spike protein and the human angiotensin-converting enzyme 2 (ACE2) receptor” NCT07583992 ↗ |
| Target | TNF | “Additionally, the formulation downregulates inflammatory mediators such as IL-6 and TNF-α” NCT07583992 ↗ |